Market Overview

Vincent Schuman, CEO, Next Generation Labs Secures Patent for Synthetic Nicotine in South Korea


Next Generation Labs awarded patent for its proprietary process for manufacturing synthetic nicotine for the vape and pharmaceutical industries

SAN DIEGO (PRWEB) August 07, 2018

Next Generation Labs CEO Vincent Schuman announced that the company has secured patent 10-1855611 for its propriety industrial process of producing ultra-high purity synthetic nicotine. Next Generation Labs is the only company in the world producing bulk quantities of non-tobacco derived synthetic nicotine.

The company has already secured its US patent rights with the USPTO for manufactured synthetic nicotine, and is thrilled to announce the patent has now been accepted by the Korean Intellectual Property Office. The quality of the synthetic nicotine prepared using the NGL patented process, delivers an ultra-pure product that exceeds the US Pharmacopeia quality standards for commercial nicotine.

Over 75 e-liquid brands around the world use Next Generation Labs' synthetic nicotine (TFN Nicotine), and the company is proud to be the single leading developer of truly synthetic nicotine that is not derived from tobacco. Brands such as NKTR, CRFT, Space Jam The Byrd, Cypher, Scala, Digable, Peel, Enfuse, Mag7, Origins, Amaranth, Rayben and Klir have experienced tremendous success with their TFN e-liquid lines, creating more vibrant flavors thanks to the attributes of TFN Nicotine. Next Generation Labs is already taking the vaping industry by storm, bringing e-juice flavors to life and enabling the creation of new markets within the industry.

"With additional USA and international patents pending, Next Generation Labs has pioneered the bulk production of synthetic nicotine, which has applications far beyond the traditional vaping market," comments Vincent Schuman, CEO, Next Generation Labs. "We strive to reinvigorate the nicotine marketplace with a quality non tobacco derived nicotine that can be used by the vape industry and the pharmaceutical industry to provide superior products for discerning adult consumers seeking alternatives to the tobacco derived nicotine products available on the market today."

Next Generation Labs sells TFN® Nicotine directly to e-liquid and pharmaceutical manufacturers; To purchase TFN® Nicotine please contact Vincent Schuman directly at Vincent(at)nextgenerationlabs(dot)com.

About Next Generation Labs
Founded in 2014, Next Generation Labs developed TFN® Nicotine, the world's leading synthetic nicotine that is not derived from tobacco. TFN® Nicotine is used in over 75 e-liquid brands and ZIA™ nicotine gum in the US and is playing a central role in helping revolutionize the pharmaceutical and vaping industries.

For the original version on PRWeb visit:

View Comments and Join the Discussion!